Supplementary Figure S9 from Reprogramming of TLR–Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer

Alterations in tumor infiltrating lymphocytes and myeloid cell populations following treatment with PSMAi-C’ dots and ICB in the Hi-Myc model (Day 10 post treatment). (a) Schematic of prostate cancer development and treatment before immunophenotyping of Hi-Myc GEM models. (b – o) Bar charts illustrating distinct T cell (b – i) and myeloid (j – o) populations harvested from Hi-Myc tumor-bearing mice (n = 3/group) treated with a multi-dose regimen (three doses every three days) of saline, ICB, PSMAi-C’dots or Dual Tx. Tumors were harvested 10 days after the final dose and dissociated to single cells, which were analyzed via multi-color flow cytometry. Data in (b – o) are presented as mean ± s.e.m. and a 1-way ANOVA with Tukey's multiple comparisons test was performed. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, ns, not significant.